207 related articles for article (PubMed ID: 27931968)
1. Borderline resectable pancreatic cancer: More than an anatomical concept.
Petrelli F; Inno A; Barni S; Ghidini A; Labianca R; Falconi M; Reni M; Cascinu S;
Dig Liver Dis; 2017 Feb; 49(2):223-226. PubMed ID: 27931968
[TBL] [Abstract][Full Text] [Related]
2. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.
Takahashi S; Kinoshita T; Konishi M; Gotohda N; Kato Y; Kinoshita T; Kobayashi T; Mitsunaga S; Nakachi K; Ikeda M
J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):567-74. PubMed ID: 21331805
[TBL] [Abstract][Full Text] [Related]
3. Multimodality management of borderline resectable pancreatic adenocarcinoma.
Prakash LR; Katz MHG
Chin Clin Oncol; 2017 Jun; 6(3):27. PubMed ID: 28705004
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of defining borderline resectable pancreatic cancer.
Kang MJ; Jang JY; Kwon W; Kim SW
Pancreatology; 2018 Mar; 18(2):139-145. PubMed ID: 29274720
[TBL] [Abstract][Full Text] [Related]
5. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer.
Kang CM; Hwang HK; Choi SH; Lee WJ
Surg Oncol; 2013 Jun; 22(2):123-31. PubMed ID: 23518243
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant therapy for resectable pancreatic cancer.
Raut CP; Evans DB; Crane CH; Pisters PW; Wolff RA
Surg Oncol Clin N Am; 2004 Oct; 13(4):639-61, ix. PubMed ID: 15350939
[TBL] [Abstract][Full Text] [Related]
7. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.
di Sebastiano P; Grottola T; di Mola FF
Updates Surg; 2016 Sep; 68(3):235-239. PubMed ID: 27629483
[TBL] [Abstract][Full Text] [Related]
8. Management of Borderline Resectable Pancreatic Cancer.
Toesca DAS; Koong AJ; Poultsides GA; Visser BC; Haraldsdottir S; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1155-1174. PubMed ID: 29722658
[TBL] [Abstract][Full Text] [Related]
9. Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement.
Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yamaue H
Pancreas; 2016 Nov; 45(10):1438-1446. PubMed ID: 27088490
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery.
Kato H; Usui M; Isaji S; Nagakawa T; Wada K; Unno M; Nakao A; Miyakawa S; Ohta T
J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):601-10. PubMed ID: 23494611
[TBL] [Abstract][Full Text] [Related]
11. Updates on the use of neoadjuvant therapy in borderline resectable pancreatic cancer.
Chandhok NS; Saif MW
JOP; 2014 Mar; 15(2):91-4. PubMed ID: 24618425
[TBL] [Abstract][Full Text] [Related]
12. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
[TBL] [Abstract][Full Text] [Related]
13. Reassessment of the clinical significance of portal-superior mesenteric vein invasion in borderline resectable pancreatic cancer.
Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Wakamatsu S; Hoshi S; Hoshi N; Hirabayashi K; Ogata Y
Eur J Surg Oncol; 2017 Jun; 43(6):1068-1075. PubMed ID: 28427822
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
[TBL] [Abstract][Full Text] [Related]
15. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
[TBL] [Abstract][Full Text] [Related]
16. Clinical Management: Resectable Disease.
White RR; Lowy AM
Cancer J; 2017; 23(6):343-349. PubMed ID: 29189330
[TBL] [Abstract][Full Text] [Related]
17. Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution.
Masui T; Nagai K; Anazawa T; Sato A; Uchida Y; Nakano K; Yogo A; Kaneda A; Nakamura N; Yoshimura M; Mizowaki T; Uza N; Fukuda A; Matsumoto S; Kanai M; Isoda H; Mizumoto M; Seo S; Hata K; Taura K; Kawaguchi Y; Takaori K; Uemoto S; Hatano E
BMC Cancer; 2022 Jan; 22(1):119. PubMed ID: 35093003
[TBL] [Abstract][Full Text] [Related]
18. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.
Isaji S; Mizuno S; Windsor JA; Bassi C; Fernández-Del Castillo C; Hackert T; Hayasaki A; Katz MHG; Kim SW; Kishiwada M; Kitagawa H; Michalski CW; Wolfgang CL
Pancreatology; 2018 Jan; 18(1):2-11. PubMed ID: 29191513
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis.
Unno M; Hata T; Motoi F
Surg Today; 2019 Apr; 49(4):295-299. PubMed ID: 30877550
[TBL] [Abstract][Full Text] [Related]
20. Definition and Management of Borderline Resectable Pancreatic Cancer.
Denbo JW; Fleming JB
Surg Clin North Am; 2016 Dec; 96(6):1337-1350. PubMed ID: 27865281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
